Skip to main content

Spinocerebellar Degeneration

8
Pipeline Programs
1
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
6
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
8 programs
2
6
KPS-0373Phase 31 trial
KPS-0373Phase 31 trial
KPS-0373, High dosePhase 31 trial
KPS-0373, High dosePhase 31 trial
KPS-0373, High dosePhase 31 trial
+3 more programs
Active Trials
NCT01004016Completed20
NCT00863538Completed40
NCT07040137Recruiting142Est. Mar 2027
+5 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Kissei PharmaceuticalKPS-0373
Kissei PharmaceuticalKPS-0373
Kissei PharmaceuticalKPS-0373, High dose

Clinical Trials (8)

Total enrollment: 779 patients across 8 trials

NCT01970124Kissei PharmaceuticalKPS-0373, High dose

A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Phase 3Completed
NCT01970111Kissei PharmaceuticalKPS-0373, High dose

An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Phase 3Completed
NCT01970137Kissei PharmaceuticalKPS-0373, High dose

A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Phase 3Completed
NCT07040137Kissei PharmaceuticalKPS-0373

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Start: Jul 2025Est. completion: Mar 2027142 patients
Phase 3Recruiting
NCT02889302Kissei PharmaceuticalKPS-0373

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Start: Nov 2016Est. completion: Mar 2018203 patients
Phase 3Completed
NCT01970098Kissei PharmaceuticalKPS-0373, High dose

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Start: Oct 2013Est. completion: Jan 2015374 patients
Phase 3Completed
NCT01004016Kissei PharmaceuticalKPS-0373

A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

20 patients
Phase 2Completed
NCT00863538Kissei PharmaceuticalKPS-0373

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

40 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 779 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.